CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


MefloquineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug365 Hydroxychloroquine + azithromycin + / - tocilizumab Wiki 1.00
drug500 Mefloquine + azithromycin + / - tocilizumab Wiki 1.00
drug360 Hydroxychloroquine Wiki 0.13

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.17
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19

Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.

NCT04347031 Pneumonia, Viral Respiratory Failure Drug: Mefloquine Drug: Hydroxychloroquine Combination Product: Mefloquine + azithromycin + / - tocilizumab Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab
MeSH:Pneumonia, Viral Pneumonia Respiratory Insufficiency
HPO:Pneumonia

Primary Outcomes

Description: The number of patients with development of respiratory failure requiring transfer to the ICU.

Measure: 1st primary endpoint for group 1

Time: up to 3 months

Description: The period of clinical recovery.

Measure: 2nd primary endpoint for group 1

Time: through study completion, an average of 3 months

Description: The period of clinical recovery.

Measure: 1st primary endpoint for group 2

Time: through study completion, an average of 3 months

Description: Frequency of fatal outcomes associated with coronavirus infection disease (COVID19)

Measure: 2nd primary endpoint for group 2

Time: through study completion, an average of 3 months

Secondary Outcomes

Description: A change in viral load by conducting PCR assay through different timeframes

Measure: 1st secondary endpoint for group 1

Time: on days 5, 10 and 90

Description: Frequency of clinical recovery on day 10 from the start of therapy

Measure: 2nd secondary endpoint for group 1

Time: on day 10

Description: The retention time of the reaction temperature from the start of treatment.

Measure: 3d secondary endpoint for group 1

Time: up to 3 months

Description: Concentration of C-reactive protein in blood plasma.

Measure: 4th secondary endpoint for group 1

Time: up to 3 months

Description: Respiratory index.

Measure: 5th secondary endpoint for group 1

Time: up to 3 months

Description: Frequency of adverse events and serious adverse events

Measure: 6th secondary endpoint for group 1

Time: through study completion, an average of 3 months

Description: A change in viral load by conducting PCR assay through different timeframes

Measure: 1st secondary endpoint for group 2

Time: on days 5, 10 and 90

Description: Respiratory index.

Measure: 2nd secondary endpoint for group 2

Time: up to 3 months

Description: The retention time of the reaction temperature from the start of treatment.

Measure: 3d secondary endpoint for group 2

Time: up to 3 months

Description: Concentration of C-reactive protein in blood plasma.

Measure: 4th secondary endpoint for group 2

Time: up to 3 months

Description: Number of patients required transition to alternative therapy schedule

Measure: 5th secondary endpoint for group 2

Time: through study completion, an average of 3 months

Description: Frequency of adverse events and serious adverse events

Measure: 6th secondary endpoint for group 2

Time: through study completion, an average of 3 months


Related HPO nodes (Using clinical trials)